Clinical Research Directory
Browse clinical research sites, groups, and studies.
Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease?
Sponsor: Tamir Ben-Hur
Summary
The goal of this clinical trial is to test whether vaccination with the BCG vaccine may improve the blood level of a biomarker of Alzheimer's disease (AD) in participants who are cognitively- and functionally- intact elderly (70-80 years old) participants, who display pathologically high levels of the blood biomarker. The main questions it aims to answer are: * Does BCG vaccination lower the plasma level of phosphorylated Tau protein (p-tau181). * Do vaccinated participants remains stable cognitively. Participants will be asked to: * Undergo cognitive and behavioral evaluation. * Receive 3 BCG vaccinations over the course of 1 year. * Perform blood tests on several occasions. All participants will be treated and followed.
Key Details
Gender
All
Age Range
70 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-07-01
Completion Date
2025-12-31
Last Updated
2025-03-18
Healthy Volunteers
Yes
Conditions
Interventions
BCG vaccine
Three intra-dermal vaccinations over a period of one year.
Locations (1)
Department of Neurology, Hadassah medical Center
Jerusalem, Israel